Document Detail

Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
MedLine Citation:
PMID:  2881788     Owner:  NLM     Status:  MEDLINE    
The antihypertensive effects of the hydralazine-related compound cadralazine (2-(3-[6-(2-hydroxypropyl)ethylamino]pyridazinyl)ethyl carbazate, ISF 2469), were investigated in 16 patients with primary hypertension concurrently treated with beta-blockers and diuretics. The protocol included a double-blind placebo controlled haemodynamic evaluation after the first tablet and two 4-week double-blind placebo controlled cross-over periods followed by an open evaluation during 2 months. Cadralazine induced a moderate, prolonged fall in blood pressure that was associated with vasodilatation and slight increases in cardiac output (dye-dilution) and heart rate. Renal plasma flow (PAH) and glomerular filtration rate (51Cr-EDTA) were not significantly influenced, but the filtration fraction was reduced. Plasma concentrations of noradrenaline and adrenaline rose, whereas plasma renin activity was unchanged. The haemodynamic parameters were not correlated with the plasma concentrations of cadralazine. During chronic cadralazine treatment the supine blood pressure was significantly lower than during the double-blind placebo phase (160/93 vs 174/102 mmHg). The compound was generally well tolerated but the body weight increased slightly (1.1 kg), probably because of fluid retention. Several patients who had previously experienced side effects with hydralazine, including one with hydralazine-syndrome, tolerated cadralazine well. This suggests that cadralazine does not cross-react with hydralazine.
B Persson; G Granerus; M Wysocki; T Hedner; O K Andersson
Related Documents :
6308068 - Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alon...
3530298 - Once a day verapamil in essential hypertension.
11978148 - Electrocardiographic and hemodynamic effects of panax ginseng.
1395118 - Clinical efficacy of perindopril in hypertension.
7920978 - Implications of a biphasic two-compartment model of constant flow ventilation for the c...
11078838 - Relationship between ocular perfusion pressure and retrobulbar blood flow in patients w...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  31     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1987  
Date Detail:
Created Date:  1987-05-06     Completed Date:  1987-05-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  513-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Adrenergic beta-Antagonists / administration & dosage*,  therapeutic use
Antihypertensive Agents / administration & dosage*,  blood,  therapeutic use
Blood Pressure / drug effects
Cardiac Output / drug effects
Clinical Trials as Topic
Diuretics / administration & dosage*,  therapeutic use
Double-Blind Method
Drug Therapy, Combination
Glomerular Filtration Rate / drug effects
Heart Rate / drug effects
Hemodynamics / drug effects*
Hypertension / drug therapy*,  physiopathology
Middle Aged
Pyridazines / administration & dosage*,  blood,  therapeutic use
Random Allocation
Renal Circulation / drug effects
Time Factors
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Antihypertensive Agents; 0/Diuretics; 0/Pyridazines; 64241-34-5/cadralazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Stimulation of hepatic efflux and turnover of glutathione by methionine in the rat.
Next Document:  Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH...